1,034
Participants
Start Date
April 8, 2014
Primary Completion Date
August 19, 2017
Study Completion Date
November 10, 2017
Stivarga (Regorafenib, BAY73-4506)
Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Multiple Locations
Lead Sponsor
Bayer
INDUSTRY